Skip to main content

Table 3 Describe incremental net benefit comparing GLP1i with DPP4i along with variance

From: Meta-analysis of economic evaluation studies: data harmonisation and methodological issues

Authors

Mean INB

(PPP adjusted US $)

Variance INB

Sinha [33]

-6,058

7,58,90,095

Davies [34]

3,063

3,05,70,369

Guillermin [35]

18,452

7,58,90,095

Lee [36]

5,267

7,58,90,095

Mezquita-Raya [37]

1,529

3,66,23,523

Steen-Carlsson [38]

-11,643

4,31,66,49,739

Perez [39]

12,007

7,18,90,710

Bruhn [40]

3,077

9,68,23,864

Roussel [41]

6,373

5,54,03,868

Barnett [42]

1,172

2,45,24,439

  1. INB incremental net benefit, PPP purchasing power parity, GLP1a Glucagon-like peptide 1 agonists, DPP4i Dipeptidyl peptidase-4 inhibitors